在一线化疗及治疗后随访期间对卵巢癌患者进行监测时，用于评估CA125升高情况的七个标准的表现。
Performance of seven criteria to assess CA125 increments among ovarian cancer patients monitored during first-line chemotherapy and the post-therapy follow-up period.
作者信息
Abu Hassan Suher O, Nielsen Dorte L, Tuxen Malgorzata K, Petersen Per H, Sölétormos György
机构信息
Department of Clinical Biochemistry, Nordsjællands Hospital, University of Copenhagen, Hillerød, Denmark.
Department of Clinical Research, Nordsjællands Hospital, University of Copenhagen, Hillerød, Denmark.
出版信息
Future Sci OA. 2017 Jul 18;3(3):FSO216. doi: 10.4155/fsoa-2017-0023. eCollection 2017 Aug.
AIM
To investigate seven CA125 criteria to monitor progressive ovarian cancer among patients with stage IC-IV disease.
MATERIALS & METHODS: Four criteria were used to asses CA125 increments starting from concentrations ≥35 U/ml and three criteria to asses increments starting from concentrations <35 U/ml.
RESULTS
A total of 231 patients were allocated to CA125 monitoring. The performances of the CA125 criteria were similar with sensitivities of 30-55%, negative predictive values of 28-46%, positive predictive values of 90-100% and median lead times of 26-87 days.
CONCLUSION
The criteria showed low sensitivity and inability to exclude progressive ovarian cancer. The study suggests that CA125 information cannot stand alone but should be considered used in conjunction with other investigative procedures.
目的
研究七种CA125标准，以监测IC-IV期疾病患者的晚期卵巢癌。
材料与方法
四种标准用于评估CA125从浓度≥35 U/ml开始的升高情况，三种标准用于评估从浓度<35 U/ml开始的升高情况。
结果
共有231例患者接受CA125监测。CA125标准的表现相似，敏感性为30-55%，阴性预测值为28-46%，阳性预测值为90-100%，中位提前期为26-87天。
结论
这些标准显示出低敏感性，且无法排除晚期卵巢癌。该研究表明，CA125信息不能单独使用，而应考虑与其他检查程序联合使用。
Zotero 插件